AUS
NZ
UK
CA
USA
IND
Highlights
- Over 100 patients treated with DurAVR® in major clinical milestone
- R&D investment ramps up for global PARADIGM Trial
- Expanded manufacturing and regulatory progress highlight Q1 momentum
Australian medtech innovator Anteris Technologies (ASX:AVR) is moving full speed ahead as it accelerates clinical activity in preparation for its global pivotal PARADIGM Trial. The company, known for its DurAVR® transcatheter heart valve (THV) system, deepened its research and development (R&D) efforts during the March quarter, with a clear focus on clinical validation and regulatory advancement.
The company recorded a net loss of US$21.9 million, up 36% from the same quarter last year, reflecting the heavy investment phase it has entered. Much of the outlay went into ramping up the clinical program, with R&D spending increasing by 42% to US$16.5 million. In contrast, general and administrative expenses declined by 13% to US$5.7 million, showcasing efficient resource allocation as Anteris scales operations.
A key milestone during the quarter was the successful submission of its Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA), a prerequisite to launching the PARADIGM Trial. This large-scale, head-to-head global study will compare DurAVR® to current market-leading TAVR devices.
Anteris also passed a significant clinical threshold—treating over 100 patients with DurAVR®, including those with de novo aortic stenosis and valve-in-valve cases. The 30-day safety and efficacy outcomes from 65 patients were reported to be clinically meaningful, setting the stage for more comprehensive trial phases. Notably, early results showed no cases of prosthesis-patient mismatch in small annuli patients—an area where traditional valves often fall short.
With operations expanding across the U.S., Canada, and Europe, Anteris has increased its manufacturing footprint, tripling capacity for 2024. New ISO-certified clean room facilities were established in both the U.S. and Australia, along with diversification of the supply chain—key components in meeting the demands of the upcoming pivotal trial.
While quarterly revenue dipped to US$0.6 million due to softer tissue product sales, the company ended the period with a strong cash position of US$49 million (A$78 million). It was also added to the FTSE Russell 2000® Index in March 2025, further strengthening its visibility in global small-cap markets.
As Anteris positions itself among emerging healthcare players in the ASX200, its innovation-driven approach and clinical achievements may attract increasing interest in the broader context of ASX dividend stocks, particularly within biotech and medtech sectors.
The company expects to initiate the PARADIGM Trial in the third quarter of 2025, pending final FDA approvals—another significant milestone in what is shaping up to be a transformative year.
